Allspring Global Investments Holdings LLC lowered its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 45.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 209,476 shares of the medical instruments supplier's stock after selling 174,963 shares during the period. Allspring Global Investments Holdings LLC owned 0.29% of OraSure Technologies worth $1,718,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in shares of OraSure Technologies by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,396,285 shares of the medical instruments supplier's stock valued at $32,000,000 after purchasing an additional 64,367 shares during the last quarter. Cannell Capital LLC lifted its stake in OraSure Technologies by 36.5% during the 3rd quarter. Cannell Capital LLC now owns 2,820,591 shares of the medical instruments supplier's stock worth $16,726,000 after acquiring an additional 753,901 shares in the last quarter. Pacer Advisors Inc. lifted its stake in OraSure Technologies by 122.5% during the 4th quarter. Pacer Advisors Inc. now owns 2,403,333 shares of the medical instruments supplier's stock worth $19,707,000 after acquiring an additional 1,323,197 shares in the last quarter. Invesco Ltd. lifted its stake in OraSure Technologies by 4.9% during the 3rd quarter. Invesco Ltd. now owns 1,282,378 shares of the medical instruments supplier's stock worth $7,605,000 after acquiring an additional 59,801 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in OraSure Technologies by 118.0% during the 3rd quarter. AQR Capital Management LLC now owns 935,510 shares of the medical instruments supplier's stock worth $5,548,000 after acquiring an additional 506,312 shares in the last quarter. Institutional investors and hedge funds own 93.50% of the company's stock.
Analysts Set New Price Targets
Separately, Evercore ISI cut their price target on OraSure Technologies from $7.00 to $6.50 and set an "in-line" rating on the stock in a report on Thursday, April 4th. Three investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $6.38.
View Our Latest Analysis on OraSure Technologies
OraSure Technologies Stock Up 3.4 %
NASDAQ OSUR traded up $0.18 during trading hours on Tuesday, hitting $5.53. 712,052 shares of the company were exchanged, compared to its average volume of 892,587. OraSure Technologies, Inc. has a 52-week low of $4.38 and a 52-week high of $8.45. The firm has a market cap of $423.10 million, a price-to-earnings ratio of 7.43 and a beta of 0.15. The company has a 50 day moving average of $6.44 and a two-hundred day moving average of $6.82.
OraSure Technologies (NASDAQ:OSUR - Get Free Report) last released its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.22 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.09. OraSure Technologies had a return on equity of 14.50% and a net margin of 13.23%. The business had revenue of $75.88 million for the quarter, compared to the consensus estimate of $74.13 million. During the same quarter in the prior year, the business posted $0.21 EPS. The business's revenue for the quarter was down 38.3% on a year-over-year basis. On average, equities research analysts predict that OraSure Technologies, Inc. will post -0.11 EPS for the current year.
OraSure Technologies Profile
(
Free Report)
OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
See Also
Before you consider OraSure Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OraSure Technologies wasn't on the list.
While OraSure Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
